DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
E•••• P••••••••• I••
Drug Discovery & Developmentgroup grade Aoff every schedule since Dec 31, 2024sponsor unattributed
Nothing material in the last 200 days. No dated change on record yet.
Mark path, consensus per quarter end
98¢ · 92¢ · 100¢ · 100¢ · 100¢Q4 2023 to Q4 2024
Principal held
at least $489,000
sum of BDC pieces, a lower bound
Fair value
$988,000
100c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
0 equity pieces beside them
Next maturity
Apr 1, 2025
$489,000 inside 24 months
On the tape since
Dec 31, 2022
latest Dec 31, 2024
Events
3
dated, non-routine
Lender marks
each lender's own fair value over cost at Dec 31, 2024, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| H••••••• C••••••• I••• | $489K | 100¢ | 0 pts |
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien S••••• S••••••, M••••••• D••• A•••• 2025, P•••• + 6.25%, F•••• rate 9.50%, 4.00% E••• Fee | $489,000 | $988,000 100c | S+625 bp |
Capital structure as the BDCs see it
latest quarter end Dec 31, 2024
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Dec 31, 2024 | at least $489,000 | 100c | S+625 bp | Apr 1, 2025 | 1 |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Dec 31, 2024 | 1 | $489,000 | $988,000 | 100c | 0 |
| Sep 30, 2024 | 1 | $489,000 | $988,000 | 100c | 0 |
| Jun 30, 2024 | 1 | $489,000 | $987,000 | 100c | 0 |
| Mar 31, 2024 | 1 | $530,000 | $950,000 | 92c | 0 |
All 9 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Dec 31, 2023 | 1 | $9.3M | $11.2M | 98c | 0 |
| Sep 30, 2023 | 1 | $4.8M | $5.3M | 98c | 0 |
| Jun 30, 2023 | 1 | $5.0M | $5.6M | 98c | 0 |
| Mar 31, 2023 | 1 | $5.0M | $5.5M | 99c | 0 |
| Dec 31, 2022 | 1 | $12.5M | $12.5M | 98c | 0 |
What changed
- Facility left every BDC scheduleDec 31, 2024
- Mark recoveredJun 30, 2024
- Marked down across lendersMar 31, 2024
- Marked down (one lender)Mar 31, 2024
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- E•••• P•••••••••derivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it